Patient Reported Outcomes in a Practice Changing Randomized Trial of Bevacizumab in the Treatment of Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

BACKGROUND: To analyze patient reported outcomes (PROs) in GOG 240, the practice-changing, randomized phase 3 trial that concluded that chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel) plus bevacizumab significantly improves overall survival (OS), progression-free survival (PFS), and resp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Penson, Richard T., Huang, Helen Q., Wenzel, Lari B., Monk, Bradley J., Stockman, Sharon, Long, Harry J., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J.A., Leitao, Mario M., Method, Michael, Michael, Helen, Tewari, Krishnansu S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4479218/
https://ncbi.nlm.nih.gov/pubmed/25638326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)70004-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller